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Background: Malignant parotid tumors are rare metastases originating from nasopharyngeal carcinoma (NPC).
This study aimed to investigate the clinicopathological features and outcome of patients with metastasis of NPC
to parotid lymph nodes after surgical therapy.
Methods: We enrolled 14 NPC patients who had metastatic disease to parotid lymph nodes after IMRT. They received
surgical treatment by total parotidectomy with neck dissection, superficial parotidectomy with neck dissection, partial
parotidectomy with neck dissection, total parotidectomy, or superficial parotidectomy. Their age, gender,
histopathology, clinical findings, and treatment outcome were analyzed.
Results: After radiotherapy, parotid metastasis represented as uncontrolled disease in three cases and as recurrent
disease in 11 cases. All the 14 patients received salvaged surgery successfully. Pathologic findings showed grade 3 in
most patients. The follow-up ranged from 11 to 120 months and the overall three- and five-year survival was 49.5%
and 37.1%, respectively.
Conclusions: Metastasis to parotid lymph nodes should be examined in NPC patients after IMRT. Resection of the
inferior parotid lymph nodes is recommended for patients with cervical metastasis, and superficial or total
parotidectomy and adjuvant therapy are recommended for intraparotid lymph node metastasis.
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A wide range of primary and metastatic neoplasms can
present as masses in the parotid gland. Roughly a quarter
of malignant parotid tumors are metastases originating
from head and neck tumors such as scalp, face, eyelid, oral
cavity, and oropharynx. Among malignant parotid tumors,
squamous cell carcinoma (SCC) and malignant melanoma
are the most common [1-3]. Nasopharyngeal carcinoma
(NPC) has a high incidence in China, especially in the
southeast.Malignant parotid tumors are rare metastases
originating from NPC. Radiotherapy is the most stan-
dardized method for NPC and the conventional dose of
radiotherapy is between 60 and 70 Gy.
The parotid space harbors three groups of lymph
nodes determined by the embryological development of
the parotid gland. The first group of lymph nodes are* Correspondence: gemhdr@126.com
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unless otherwise stated.embedded within the parotid fascia, the second group in
the parotid parenchyma, and the last group such as the
preauricular lymph nodes remain extrafascial and extra-
glandular. Although metastases to parotid lymph nodes
are uncommon, it should always be considered in the
differential diagnosis of a parotid mass. In this study we
aimed to review and investigate the clinicopathological
features and outcome of patients with metastasis of
NPC to the parotid lymph nodes.Methods
This study was conducted according to the Declaration of
Helsinki on biomedical research involving human subjects.
The study protocol was approved by Ethics Committee of
Zhejiang Cancer Hospital. The approval number is zjzlyy
[2014]-11-96. We retrospectively reviewed the records of
patients with NPC in Zhejiang Cancer Hospital between
January 2001 and December 2012. Among all 9,602 cases
of NPC, 14 patients had metastasis of NPC to parotid
lymph nodes after IMRT and received salvaged surgicalThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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supine position and to wear a plastic head and neck
mask. The primary tumor and whole neck were treated
by IMRT. The total dose was 69 Gy in 30 fractions at
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ANED: Alive with no evidence of disease; AWD: Alive with disease; CRT: Chemothera
M: Distant metastasis; ND: Neck dissection; PP: Partial parotidectomy; RT: Radiothera
TP: Total parotidectomy.(PGTV), 66 Gy to the positive nodal gross target volume
(GTV) node, 63 Gy to the planning target volume
(PTV) node, 60 Gy to the high-risk neck regions, and
54 Gy to the low-risk neck regions. PGTV included
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py and radiotherapy; DOD: Dead of disease; G: Grading; LR: Local recurrence;
py; S: Surgery; SCC: Squamous cell carcinoma; SP: Superficial parotidectomy;
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by a stationary, multileaf intensity-modulating collimator
(Varian, Palo Alto, California, United States). All targets
were treated simultaneously using the simultaneous
integrated boost technique.
Patients were considered eligible for the radiation
treatment if they had histologically confirmed NPC with
metastasis to parotid lymph nodes, including the uncon-
trolled disease (indicating that residual tumors remain after
IMRT) and delayed metastasis. Patients with primary par-
otid malignancies, lymphomas, history of a second primary
tumor, direct tumor extension to the parotid gland or ad-
vanced untreatable disease were excluded from this study.
A total of 14 patients met the study criteria and their
data such as the age, gender, histopathology, clinical
findings, and treatment outcome were analyzed. The
mean and median follow-up period after treatment of
metastatic disease was 55.5 and 34.0 months, respect-
ively (range: 11 to 120 months). Survival analysis was
performed using the Kaplan-Meier method.Figure 1 MRI image of uncontrolled parotid metastasis of nasopharyn
were observed in bilateral carotid sheath and pharyngeal lymph node areaResults
The characteristics of the 14 patients were shown in
Table 1. The patients included 12 male and two female.
Age ranged from 18 to 74 years (mean: 50.4 years). The
pathological diagnosis of the primary tumors was grade
3 (poorly differentiated carcinoma) in most of the patients.
A total of three patients were identified as uncontrolled
disease of parotid metastasis because lesions recurred
within three months after the initial treatment of radio-
therapy. Among the delayed metastasis of parotid group,
the mean time interval between the treatment of the pri-
mary tumor and the diagnosis of metastatic disease to the
parotid gland was 55.9 months (range: 15 to 108 months).
All patients presented with a clinically palpable parotid
metastatic mass on physical examination. A total of six
patients (42.9%) had additional enlarged cervical lymph
nodes. The most common location of metastases within
the parotid gland was the inferior or superficial parotid
nodes, and four patients had positive nodes in both the
superficial and deep parotid nodes.geal carcinoma after radiotherapy. Multiple swollen lymph nodes
.
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their initial treatment. Magnetic resonance imaging (MRI)
confirmed uncontrolled parotid metastasis parotid metas-
tasis in three patients and the typical MRI image for one
patient is shown in Figure 1.
For the other 11 patients, MRI imaging confirmed de-
layed parotid metastasis and the typical MRI image for
one patient is shown in Figure 2. Among the 11 patients
presenting with delayed parotid metastasis, three cases
underwent surgery and adjuvant radiotherapy, three
cases underwent surgery, adjuvant radiotherapy, and/or
chemotherapy, and five cases underwent surgery alone.
The surgery procedure for the treatment of parotid me-
tastasis was as follows: total parotidectomy with neck
dissection, superficial parotidectomy with neck dissec-
tion, partial parotidectomy with neck dissection, total
parotidectomy, and superficial parotidectomy.
Postoperative complications included facial paralysis or
partial facial paralysis, parotid fistula, and flap necrosis. At
the last follow-up assessment after treatment of parotidFigure 2 MRI image of delayed parotid metastasis of nasopharyngeal
observed in the left parotid gland.lymph nodes, tumor recurrence occurred in three patients
and five patients showed distant metastasis. A total of
eight patients died of disease, three patients were alive
with no evidence of disease, and three patients were alive
with disease. The overall three- and five-year cumulative
survival was 49.5% and 37.1%, respectively. The medium
survival was 34 months (Figure 3).
Discussion
The incidence of NPC is high in China, especially in the
southeast, including the Zhejiang province. Radiotherapy
is the main treatment method for NPC and the usual
dose of radiotherapy is between 60 and 70 Gy. With the
development of IMRT, the protocols for NPC radiother-
apy have been improved. To prevent the occurrence of
xerostomia, the dose of IMRT is regulated. Normally, the
dose for the radiation of parotid gland is limited to V26 to
30 < 50%. However, for any radiotherapy technique that
involves facial and cervical joint field and auriculotem-
poral field in the facial and cervical regions, the dose forcarcinoma after radiotherapy. A nodule about 2.4 × 1.4 cm was
Figure 3 Kaplan-Meier curve estimating the post-operative overall survival of 14 patients presenting with metastasis of nasopharyngeal
carcinoma to parotid lymph nodes.
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This may explain why the incidence of NPC metastasis to
parotid gland has recently increased with the application
of IMRT.
The parotid lymphatics are known to receive drainage
from a wide region of the head and neck [4,5]. Parotid
nodes are divided into superficial and deep groups based
on the relation to facial nerve. Lymph nodes are present
in superficial and deep lobes of the gland. The superficial
and deep lobe has 3.9 to 7.6 and 1.05 to 2.3 lymph
nodes, respectively [6,7]. These intraparotid lymphatics
render the parotid uniquely susceptible to tumor metas-
tasis [8]. However, pathological findings have shown that
all the parotid lymph nodes lie lateral to the retroman-
dibular vein and not the facial nerve, thus any dissection
that follows the nerve may leave residual disease because
of anatomical variation in the position of the facial vein
relative to the nerve [9].
Pathologic findings showed grade 3 tumors in most of
the patients. We observed the correlation of increased
risk of parotid node involvement with an increased
number of cancer-positive cervical lymph nodes, consist-
ent with a previous study [10].
Due to parotid node metastasis, it is important to have
a careful clinical and radiographic evaluation of the
parotid region in a patient with NPC cancer and cervical
metastasis. During neck dissection, careful intraopera-
tive inspection and palpation of the parotid should beperformed. We recommend the removal of parotid tail
nodes if metastatic involvement is suspected. There is
still controversy on the selection of surgery to treat
metastasis to parotid lymph nodes; while some sur-
geons prefer superficial parotidectomy, others prefer
total parotidectomy [11]. Facial nerve preservation should
be attempted unless the nerve is grossly involved with
tumor.
In the present study, amongst the six patients who
underwent a total parotidectomy, four were diagnosed with
metastasis within the deep lobe. Therefore, we think that
total parotidectomy is necessary due to the poor prog-
nosis of untreated deep-lobe metastasis, although it could
increase the risk of temporary facial nerve dysfunction.
Metastatic disease to the parotid gland is mostly caused
by SCC of the head and neck, and long-term survival
remains poor despite combined treatment modalities
[12]. Several studies reported positive surgical margins,
extranodal spread, advanced tumor stage, and the absence
of adjuvant irradiation as factors of poor locoregional
control [13,14]. Combination therapy with surgery and
radiotherapy has been shown to be effective to improve
the survival of patients with advanced head and neck
cancer [14,15]. In terms of timing, surgery is considered
the first and best option for patients deemed suitable
for that, after a careful pre-operative risk-assessment.
In cases of extranodal spread and advanced tumor
stage, radiotherapy and/or chemotherapy are needed.
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The application of IMRT should be taken into account
for metastatic disease to the parotid gland. Metastasis to
the parotid lymph nodes should be examined in patients
with NPC before initial treatment and after IMRT. For
patients with substantial cervical metastasis, we recom-
mend the resection of the tail of the parotid gland and
the inferior parotid lymph nodes during the neck dissec-
tion. If intraparotid lymph node metastases are detected,
we recommend total parotidectomy and adjuvant therapy.
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